Combined effect of bumetanide, bromide, and GABAergic agonists: An alternative treatment for intractable seizures  by Almeida, Antônio-Carlos G. et al.
Epilepsy & Behavior 20 (2011) 148–150
Contents lists available at ScienceDirect
Epilepsy & Behavior
j ourna l homepage: www.e lsev ie r.com/ locate /yebehLetter to the EditorCombined effect of bumetanide, bromide, and GABAergic
agonists: An alternative treatment for intractable seizures
To the Editor:
The epilepsies constitute one of the most common serious brain
disorders and know no geographic, social, or racial boundaries,
occurring in men and women and affecting people of all ages, though
more frequently affecting young people in the ﬁrst two decades of life
and people over the age of 60 [1,2]. Worldwide, there are at least
50 million people who have epilepsy, and many of these persons have
seizures that are refractory to treatment with the currently available
therapies [1,3,4]. The most common risk factors for epilepsy are
cerebrovascular diseases, brain tumors, alcohol, traumatic head injuries,
genetic inheritance, andmalformations of cortical development [5,6]. In
resource-poor countries, endemic infections such as malaria and
neurocysticercosis seem to be major risk factors [7].
The paradoxical excitatory action of GABAobserved in the immature
brain plays a role in neonatal development [8,9], but also is responsible
for the increased seizure propensity and lowered seizure threshold of
neonates [10]. Differently frommature neurons of adults, the immature
neurons of neonates exhibit amuch higher [Cl–]i induced by higherNa+,
K+,2Cl– co-transporter type 1 (NKCC1) expression and lower K+,Cl–
type 2 (KCC2) expression. In this circumstance, the activation of GABAA
receptors is followed by an efﬂux of Cl–, induced by the positivity of the
Nernst potential for Cl– with respect to the membrane potential, which
accounts for the excitatory action of GABA.
Almost all neurological insults (hypoxia–ischemia, metabolic
derangement, hemorrhage, and infection) sustained during the
neonatal period can trigger the synchronous ﬁring of hyperexcitable
neurons that underlie epileptogenesis [11]. Investigations conducted
in human epileptogenic tissue have shown that dysplastic tissue
may retain immature properties, exhibiting mechanisms of seizure
generation resembling that observed during development in the
immature brain [12,13].
To unravel the mechanisms involved in seizure initiation,
epileptogenesis, and spontaneous recurrent seizures and to search
for new treatment options, several experimental models mimicking
different aspects of the epileptic process have been developed. Along
with the seizure induction process, which leads to spontaneous
seizures, many studies conducted with experimental models have
identiﬁed activation of an inﬂammatory state [14]. Concomitantly
with the inﬂammation, changes in expression of NKCC1 and KCC2 co-
transporters have been observed that resemble the immature brain
[15]. An increasing number of investigations suggest an important
role for cation chloride co-transporters in controlling neuronal
functions [6]. Deregulation of their expression may contribute to the
mechanisms of hyperexcitability, which, in combination with neuro-
nal coupling, may lead to synchronization and, therefore, to seizures.
The hyperexcitability is attributed mainly to the accumulation of1525-5050 © 2010 Elsevier Inc.
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the nonsynaptic coupling promoted by the decrease in extracellular
space volume [16,17].
Neurophysical studies of the molecular mechanisms that underlie
the hyperexcitation and synchronization of neurons have a proﬁtable
role in the search for targets for novel antiepileptic drugs to control
seizures that affect mainly infants. The treatment of refractory seizures,
normally associatedwith intracellular chloride accumulation, involves a
complex interaction of the mechanisms responsible for controlling
the intracellular chloride level. Combining multiple drugs, each one
targeting a different mechanism, is a promising powerful strategy to be
investigated. It can be conjectured that more efﬁcient action would be
coupled with fewer side effects, as each compound would be used at a
low dose, presuming their synergistic effect on the system.
Initially, attention to cation chloride co-transporters (CCCs) focused
on their physiological roles in the recovery of cell volume after swelling
or shrinkage in hypotonic or hypertonic media [18]. Later, attention
turned to the importance of CCCs in regulation of intracellular Cl– in the
central nervous system (CNS) [19]. In mature brain, the normal level
of intracellular chloride must be low enough to establish inhibitory
GABAergic neurotransmission. This condition is due to minimal NKCC1
expression but robust KCC2 expression.
Chloride accumulation, typical of immature brain, as well as some
adult epilepsy syndromes, is promoted by the equilibrium established
by the resulting changes in the expression of NKCC1 and KCC2.
Investigation into themechanisms involved revealed that co-transporter
activities, driven by gradients established by Na/K pumps [20], have the
net effect of controlling the intracellular chloride level. Studies
conducted by our research group, based on computational simulation,
have also shown the importance of the interplay between these
mechanisms to determination of the excitability level [16]. The
KCC co-transporter is responsible for Cl– extrusion, counteracted by Cl–
inﬂux, promoted by NKCC co-transporters. The simulations reproduce
the Cl– accumulation corresponding to an extracellular K+ increase,
typical of intense neuronal ﬁring.
Granule cells of animals with epilepsy induced with pilocarpine
exhibit a positive shift in the GABA reverse potential, EGABA [15,21].
This shift in EGABA alters synaptic integration, increasing granule cell
excitability, and results in compromised “gate” function of the dentate
gyrus.
Investigations have been carried out on the use of co-transporter
inhibitors, such as furosemide and bumetanide, as antiepileptic agents
[21,22]. These studies, conducted in hippocampal slices, suggest that
blockage of NKCC is critical to the antiepileptic effects of chloride
transport antagonism [23]. This fact was also conﬁrmed by compu-
tational simulation [16]. According to these simulations, Cl− accu-
mulation in the intracellular space during the ictal state is mediated
by the NKCC co-transporter, and occurs with almost the same ﬂux as
in the ictal state. Cl− efﬂux is dominated by the KCC co-transporter
and during the ictal state it is always smaller than Cl− NKCC inﬂux.
Only at the transition between the ictal and interictal states does KCC
efﬂux overcome NKCC inﬂux and cause a decrease in intracellular Cl−
Fig. 1. Block diagram indicating the systemic action of the conjoint effect of bumetanide, bromide, and GABAA agonist. Bromide acts by blocking NKCC activity. This co-transporter is
responsible for Cl– inﬂux, which induces the accumulation of this ion in the intracellular space, inducing an increase in excitability. An NKCC antagonist is, therefore, able to
counteract the chloride accumulation, decreasing excitability. Bromide acts directly on EGABA, improving its negativity and also decreasing excitability. The conjoint effects of an NKCC
antagonist and bromide are therefore complementary. The clinical observation of seizure reduction could be indicative of induced EGABA negativity with respect to Vm (intracellular
potential), when the use of GABAergic drugs can be useful. NKCC=Na+, K+, 2Cl– co-transporter; EGABA=GABA reverse potential.
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target for antiepileptic drugs, and bumetanide has been highlighted
for its adequacy. Bumetanide has an approximately 500-fold greater
afﬁnity for NKCC1 (Ki=~0.1 μM) than for KCC2 (Ki=~25–50 μM); in
contrast, furosemide inhibits NKCC1 and KCC2 with equal potency
(Ki=~25–50 μM). Therefore, at low doses (2–10 μM), bumetanide is a
relatively speciﬁc inhibitor of NKCC1 [24].
Bromides were the ﬁrst effective treatment for epilepsy. Intro-
duced in 1853 by Sir Charles Locock, bromides remained useful as a
therapeutic option for nearly 60 years. With the advent of less toxic
and more effective treatments, the use of bromides became less
common [25]. However, bromides are still a valuable tool in the
treatment of epilepsies refractory to current antiepileptic drugs, such
as medically refractory tonic–clonic seizures and severe pediatric
myoclonic epilepsies [26–28]; the pharmacological activity of bro-
mides remains incompletely elucidated.
The most acceptable hypothesis explaining how bromide blocks
epileptic activity is through an increase in neuronal hyperpolarization
mediated by inhibitory postsynaptic potentials [29]. The antiepileptic
effect of bromide is believed to be due to the potentiation of inhibitory
postsynaptic potentials by GABA, as Br– ions cross cellular membranes
more quickly than Cl–, enhancing GABA-activated currents and
leading to large hyperpolarization [30]. But not only are GABA-activated
chloride channels more permeable to bromide, voltage-dependent
channels are also more permeable (INBrNClNF, 1.98:1.46:1:0.44) [31].
This fact justiﬁes why bromide also has effects on nonsynaptic
epileptiform activity (NEA). Meierkord et al. [32] observed consistent
blockage of NEA when hippocampal slices bathed with low-Ca2+
solution were perfused with 11 mM NaBr. If bromide would also
substitute for chloride in the CCCs, no objectionwould be considered to
the assumption that bromide also accumulates intracellularly. Because
this is not the case, bromide may exert antiepileptic activity not only
because of its reinforcement of the Cl– hyperpolarizingNernst potential,
but also because of its low afﬁnity for the NKCC enzyme in comparison
with Cl– [33,34]. In summary, bromide's antiepileptic effect may be
divided into three parts: (1) compensation of Cl– accumulation by
meansof its hyperpolarizingeffectonchloridechannels; (2)antagonism
of chloride ﬂow through the channels because of its competition with
chloride; (3) low afﬁnity for the NKCC enzyme.
We propose the therapeutic use of bumetanide and bromide
combined for the treatment of patients with refractory epilepsy.Bumetanide would reduce intracellular chloride concentration and
bromide would reinforce EGABA negativity, according to Fig. 1, where
the systemic effects of bumetanide and bromide are depicted.
Although acting by different mechanisms, both drugs reduce neuronal
excitability. Once the effects are complementary, the doses of
bumetanide and bromide could be reduced and, consequently, their
side effects as well. In fact, in a recent case report on the use of
bumetanide for treatment of autism, the authors did not observe, at
the dosage investigated, any side effect [31]. To overcome the severe
side effects of bromide described [32], it is paramount that bromide be
administered with care, that follow-up testing be carried out, and that
serum bromide levels bemonitored periodically.We also propose that
effort should be directed to ﬁnd anions or anionic compounds that can
replace bromide with the aim of avoiding its side effects. These
proposals reﬂect a new perspective on the use of bromide: valuing its
clinical efﬁcacy associated with a reduction of its side effects.
Furthermore, we also hypothesize that clinical observation of seizure
reduction would be indicative of EGABA negativity (Fig. 1). Under such
clinical conditions, after the effect of bumetanide and bromide has
already been established, shifting GABA from excitation to inhibition,
the administration of GABA agonists should be considered in the
treatment of uncontrollable seizures. With the action of these
agonists, it is assumed that the doses of bumetanide and bromide
could be reduced further.
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